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Pituitary adenomas occur in a familial setting in multiple endocrine neoplasia type 1 (MEN1) and
Carney’s complex (CNC), which occur due to mutations in the genes MEN1 and PRKAR1A
respectively. Isolated familial somatotropinoma (IFS) is also a well-described clinical syndrome related
only to patients with acrogigantism. Pituitary adenomas of all types – not limited to IFS – can occur in
a familial setting in the absence of MEN1 and CNC; this phenotype is termed familial isolated pituitary
adenomas (FIPA). Over the past 7 years, we have described over 90 FIPA kindreds. In FIPA, both
homogeneous and heterogeneous pituitary adenoma phenotypes can occur within families; virtually
all FIPA kindreds contain at least one prolactinoma or somatotropinoma. FIPA differs from MEN1 in
terms of a lower proportion of prolactinomas and more frequent somatotropinomas in the FIPA cohort.
Patients with FIPA are significantly younger at diagnosis and have significantly larger pituitary
adenomas than matched sporadic pituitary adenoma counterparts. A minority of FIPA families overall
(15%) exhibit mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene; AIP
mutations are present in only half of IFS kindreds occurring as part of the FIPA cohort. In families with
AIP mutations, pituitary adenomas have a penetrance of over 50%. AIP mutations are extremely rare
in patients with sporadic pituitary adenomas. This review deals with pituitary adenomas that occur in
a familial setting, describes in detail the clinical, pathological, and genetic features of FIPA, and
addresses aspects of the clinical approach to FIPA families with and without AIP mutations.
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The etiology of pituitary tumors is an issue that
provokes continued interest among endocrinologists.
This interest stems from the variability in clinical
presentation and symptom burden, the unpredictability
of tumor growth, and the often complex management.
Historically, there has been considerable uncertainty
concerning the actual prevalence of pituitary tumors,
with a lack of connection between data from autopsy
and radiological series and clinical data. Assessments
based on unselected populations undergoing autopsy or
magnetic resonance imaging (MRI) suggest that
pituitary tumors – almost invariably anterior pituitary
adenomas – occur very frequently. A meta-analysis
suggested a mean pituitary tumor prevalence of 14.4
and 22.5% in autopsy and radiological series respect-
ively (1). In contrast, the few epidemiological studies
performed in the past indicated that pituitary tumors
occurred infrequently, with a rate of 190–280 cases/
million (1:3571 to 1:5263 individuals) being reported
overall (2). Between these two extremes lies the most
practically relevant information, namely the prevalence
of clinically apparent pituitary tumors or those tumorsn Journal of Endocrinologythat utilize health care resources during their diagnosis,
treatment, and follow-up. Recently, we reported some of
the first evidence regarding clinically apparent pituitary
adenoma prevalence in the modern era. This newer
epidemiological evidence suggests that pituitary adeno-
mas occur relatively frequently in the general popu-
lation, with an overall rate of one case in 1064 of the
population (3). These results indicate that clinically
apparent pituitary adenomas are more than three times
more common than previously thought, which in turn
increases the need to understand the pathophysiological
mechanisms that give rise to these tumors.
A wealth of studies have been conducted on the
molecular genetics of pituitary adenomas in an effort to
determine their pathophysiology. Mutations in a series of
genes, some relatively frequent and some rare, have been
described and characterized in the experimental setting.
Chief among these is the gsp gene that encodes the
a-subunit of the Gs, a heterotrimeric G-protein. Activating
mutations in gsp lead to constitutive activation of Gsa,
increased adenylyl cyclase activity and overproduction of
cAMP. Up to 40% of somatotropinomas have mutations in
gsp (4). Other genetic abnormalities associated with
pituitary tumorigenesis or abnormal proliferative charac-
teristics are listed in Table 1.DOI: 10.1530/EJE-07-0348
Online version via www.eje-online.org
372 A Beckers and A F Daly EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007) 157While many genetic abnormalities have been
described in the setting of pituitary adenomas, few are
involved in familial or inherited conditions. Familial
pituitary tumors account for w3% of pituitary
adenomas (5). Multiple endocrine neoplasia type 1
(MEN1) and Carney’s complex (CNC) are well-charac-
terized inheritable syndromes that are associated with,
among other features, pituitary adenomas. Isolated
familial somatotropinomas (IFS) have been recognized
as occurring in a familial setting for some time and the
genetic pathophysiology has been the subject of intense
interest. Over the last 7 years, a newer clinical
condition, termed familial isolated pituitary adenomas
(FIPA), has emerged, which encompasses a wider
spectrum of pituitary adenomas occurring in a familial
setting than only somatotropinomas. This review
addresses the features of pituitary disease occurring in
the familial setting with particular attention on recent
information concerning the clinical, pathological, and
genetic features of FIPA.Familial causes of pituitary adenomas
MEN1
MEN1 syndrome, an autosomal dominant disease
caused by mutations in the MEN1 gene on chromosome
11q13 that encodes the regulatory protein menin, is
characterized by the presence of typical patterns of
endocrine active and inactive tumors and non-endo-
crine tumors (6). In patients with mutations in the
MEN1 gene, pituitary adenomas occur in w40% of
cases (7). These data are supported by murine models of
men1 gene knockout, in which w37% of heterozygotic
animals had pituitary tumors in adulthood (8). While
no genotype–phenotype relation has been shown
among the hundreds of MEN1 mutations nowTable 1 Genetic mutations or alterations occurring in the setting of p
Gene Defect
Cyclin D1 Overexpression in non-secreting ade
Gsp Somatic activating mutations in up to
Mosaicism in McCune–Albright synd
syndrome in association with prec
PRKAR1 Truncation mutations in Carney’s co
Pdt-FGFR4 Alternative transcription initiation in p
PTTG Increased expression in more aggre
BMP-4 Diminished expression in prolactinom
GADD45G Promoter methylation in non-secretin
MEG3a Promoter methylation in non-secretin
MEN1 Inactivating mutations in all pituitary
PKC Point mutations in invasive pituitary
p16 Promoter methylation in pituitary ade
CDKN1B (p27Kip1) Germline heterozygous nonsense m
Retinoblastoma Promoter methylation in pituitary ade
ZAC Promoter methylation in non-function
AIP Germline mutations and loss of hete
somatotropinomas, somatolactotro
Cushing’s disease (sporadic only)
www.eje-online.orgdescribed, in familial MEN1, pituitary disease is
significantly more frequent than in sporadic MEN1
cases (9). Prolactinomas predominate in MEN1, are
larger than their sporadic counterparts and have a
poorer response to dopamine agonist therapy (7).
In MEN1, pituitary tumors are twice likely to be
macroadenomas than in cases of sporadic pituitary
adenomas (85% vs 42% respectively). In keeping with
this, tumor signs caused by local compression are more
frequent in MEN1 than in sporadic pituitary tumors.
Females with MEN1 have an increased risk of
developing a pituitary tumor and acromegaly demon-
strates a female preponderance in the setting of MEN1
(7). Despite the in-depth characterization of MEN1
clinically and genetically, more than 20% of cases with
clinical features characteristic of MEN1 have no
demonstrable genetic mutation, raising the possibility
of the involvement of other genes in this syndrome.
Recently, a mutation in the CDKN1B gene, which codes
for the cyclin-dependent kinase inhibitor p27Kip1, was
shown to lead to a MEN1-like syndrome in a rat model
and a human kindred (10). In the human setting, a
germline nonsense mutation in the CDKN1B gene on
chromosome 12 was associated with acromegaly,
primary hyperparathyroidism, renal angiomyolipoma,
and testicular cancer among various members of the
kindred. A second patient with a MEN1-like phenotype
and no MEN1 mutation was recently identified as
having a CDKN1B gene mutation (11). The female
patient had a small-cell neuroendocrine cervical
carcinoma (in which loss of heterozygosity (LOH) for
CDKN1B and lack of p27 protein staining were found),
Cushing’s disease, and hyperparathyroidism. No
relevant family history of MEN1-like features was seen
and limited family screening (one brother) was negative.
Despite the MEN1-like features of the patients described,
studies from Ozawa and colleagues at the NIH and fromituitary adenomas.
nomas and somatotropinomas
40% of somatotropinomas
rome (somatotropinoma, somatomammotropinoma, and Cushing’s
ocious puberty, hyperthyroidism, and dermal and bony lesions)
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utation in MENX, a novel, rare MEN1-like syndrome
nomas
ing adenomas
rozygosity in 15% of FIPA cases. Seen in familial/sporadic
pe adenomas, prolactinomas, non-secreting adenomas, and
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to account for only a minority of patients with a
MEN1 phenotype in the absence of MEN1 gene
mutations (11, 12)CNC
CNC is a rare predominantly familial condition
characterized by lentigines, myxomas, Schwann cell
tumors, adrenal hyperplasia, and pituitary abnormal-
ities (13, 14). CNC is associated with mutations in the
protein kinase A Ia regulatory subunit gene
(PRKAR1A) in 60% of cases (15). Pituitary disease in
CNC is characterized by frequent (up to 75% of cases)
hypersecretion of prolactin, growth hormone (GH), and
insulin-like growth factor-I (IGF-I), which can lead to
acromegaly in occasional cases. Acromegaly in CNC is
not particularly aggressive, with a mean age at
diagnosis of 35.8 years in the largest series from
Stratakis’s group at the National Institutes of Health
in the United States (16). One particular feature of
pituitary tumors in CNC is the presence of somato-
mammotropic cell multifocal hyperplasia that occurs
against a background of normal pituitary and may give
rise to adenomas (17). Interestingly, murine models of
CNC with prkar1a knockout, while mirroring many of
the tumor abnormalities seen in humans, do not
develop marked pituitary disease.Isolated familial somatotropinomas
IFS, defined asR2 cases of acromegaly or gigantism in a
family in the absence of MEN1 or CNC, has long been
recognized as a clinical entity. If members of the FIPA
cohort are included, more than 50 IFS families
including over 120 individuals have now been described
in the literature (18–20). IFS is characterized by a slight
male predominance and a much younger age at onset
(25 years) when compared with sporadic acromegaly,
with gigantism being a characteristic feature of IFS
kindreds. Tumors in patients with IFS are almost
invariably macroadenomas. Before the identification of
aryl hydrocarbon receptor-interacting protein (AIP)
gene mutations as a potential culprit in some cases of
non-MEN1, non-CNC familial pituitary tumorigenesis
(21), genetic linkage in IFS to a defined region of
chromosome 11q13 was well demonstrated by the
collaborative efforts of Frohman, Teh, Gadelha, and
others (19, 22, 23). Indeed, by 2004, Luccio-Camelo
et al. had narrowed the linkage to between micro-
satellite markers D11S956 and D11S527 on chromo-
some 11q13.1-q13.3 (24). Despite the advent of
mutations in AIP as potential causative features in
IFS, the genetic pathophysiology of IFS remains to be
fully described as we have found that in 50% of IFS
families, no AIP mutations exist (25).FIPA
Background
In the late 1990s, we became interested in the issue of
pituitary adenomas that occurred in a familial setting
but were not related to MEN1 or CNC (19). As noted
above, IFS had been clearly identified as a clinical entity
(19). Little or no evidence of familial links in the setting
of other pituitary tumor phenotypes had been published
and apart from a handful of case reports on familial
prolactinoma (26, 27), Cushing’s disease (28), and non-
secreting (NS) adenomas (29), there had been no
organized effort to study the clinical and genetic
characteristics of other pituitary tumors occurring in
a familial setting. At our own center, we began to collect
and classify kindreds with two or more pituitary
adenomas of any type that were unrelated to MEN1 or
CNC, a clinical condition that we termed FIPA. In our
initial single-center study in 2000, we identified 27
patients who came from FIPA families, which con-
stituted w1% of our total pituitary adenoma patient
population (30). At that early stage, we noted that
patients within the same family could exhibit either the
same pituitary tumor type or different tumor types;
these were classified as homogeneous and hetero-
geneous FIPA kindreds respectively. In order to expand
the cohort, we began a multicenter collaborative study
among tertiary referral centers in France, Italy, and the
United States. By 2002, this collaboration had led to the
identification and the clinical and genetic character-
ization of 80 patients among FIPA cohorts (31). Further
expansion to 22 centers in France, Italy, and The
Netherlands permitted the identification of 64 FIPA
kindreds in 2004 which included w140 patients (32).
At that time, the study was closed and a full series of
clinical, biochemical, radiological, and pathological
analyses were performed on the entire group. Since
then, FIPA kindreds have continued to be reported and
more than 90 families have been identified worldwide
by our collaborative group.
As an initial step to delineate the profile of patients
with FIPA, we undertook a detailed retrospective study
of the most clinically relevant features of these FIPA
kindreds, namely their hormonal, radiological, and
pathological characteristics (18). At least one affected
member of each FIPA kindred underwent MEN1 genetic
screening, while negative family history and a normal
serum calcium and parathyroid hormone (and normal
gastrin, vasoactive intestinal polypeptide, and pancrea-
tic polypeptide levels wherever available) were used to
rule out MEN1 clinically in all patients. CNC was ruled
out by the sequencing of the PRKAR1A gene in one
affected member of each family exhibiting homogeneous
GH-secreting tumors; thorough clinical profiling and
echocardiography were also performed to exclude other
CNC features, such as cardiac myxomas in patients with
acromegaly. In order to assess whether there werewww.eje-online.org
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pituitary tumor patients, a control group of 288 non-
MEN1, non-CNC sporadic pituitary patients, was
analyzed. This control series was matched with the
FIPA cohort for the year of diagnosis.
We used a combination of biochemical and clinical
data to classify pituitary tumors according to their
secretory profiles as prolactinomas, somatotropinomas,
somatolactotrope tumors, Cushing’s disease (adreno-
corticotropin-secreting tumors), and thyrotropin (TSH)-
secreting tumors. Gonadotropinomas and NS tumors
were grouped separately. Tumors were assessed using
computed tomography (pre-1986) or MRI, and were
classified as microadenomas (%10 mm), macroadeno-
mas (O10 mm), or giant adenomas (O40 mm);
invasive characteristics (cavernous or sphenoid sinus)
were also assessed. Surgical findings were collected and
analyzed to add direct visual information about tumor
size and invasion; results of immunohistochemistry for
pituitary hormones were collected wherever available.Clinical characteristics
Among the FIPA cohort, families with two, three, and
four affected members are seen (18, 25). FIPA is
characterized by a predominance of prolactinomas
and GH-secreting tumors, which account for about
75% of the cohort (Fig. 1). There is a female
preponderance (62%) which may be related to the
frequent occurrence of prolactinomas in women within
the FIPA cohort. Affected members are mainly close
relatives, with 74.6% demonstrating a first-degree
relationship (i.e. sibling or filial relationships). As
noted above, it had been evident for some years that
the tumor phenotype within individual FIPA kindreds
could present homogeneously or heterogeneously. FIPA
is divided evenly between homogeneous andwww.eje-online.orgheterogeneous kindreds. In heterogeneous FIPA kin-
dreds, all tumor phenotypes can occur, but almost
invariably at least one prolactinoma or GH-secreting
adenoma is seen per family.
Patients from FIPA kindreds are younger at diagnosis
– on average 4 years younger – than patients with
sporadic pituitary adenomas. When multi-generational
families are assessed separately, patients from the later
generations (children and grandchildren) have a
significantly younger mean age at diagnosis as
compared with their forebears (29.0 vs 50.5 years,
P!0.0001). It is not known whether this generational
effect is related to some form of anticipation at the
genetic level, or earlier disease recognition due to
increased awareness on the part of parents. Patients
from homogeneous FIPA kindreds are significantly
younger at diagnosis than their heterogeneous kindred
counterparts; this effect is significant following multi-
variate analysis correcting for tumor type.
Overall, tumors from FIPA patients have size charac-
teristics similar to those of the general sporadic pituitary
tumor population. Macroadenomas occur in 63% of
FIPA cases and about two-thirds of sporadic cases, and
the rates of suprasellar extension and invasion of
surrounding tissues do not differ between FIPA and
sporadic pituitary tumors. Tumors from heterogeneous
FIPA kindreds are more frequently macroadenomas
than in the homogeneous FIPA group (72% vs 53%
respectively; P!0.04). This is due to a predominance of
NS tumors in the former group (all macroadenomas)
and a high frequency of microprolactinomas among
homogeneous FIPA kindreds.
Characteristics by tumor type
† Prolactinomas comprise about 40% of tumors that
occur in the setting of FIPA and as a whole do notFigure 1 Composition of the FIPA cohort by
tumor phenotype.
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presentation in second to fourth decades of life,
microadenomas (33)). All males with prolactinomas
in the FIPA cohort had macroadenomas, again in
keeping with more aggressive disease in males from
the sporadic population. Prolactinomas appear more
aggressive when they occur in heterogeneous FIPA
kindreds, with suprasellar extension and cavernous
sinus invasion being significantly more frequent
than in sporadic prolactinomas. Furthermore, the
only malignant prolactinoma that occurred at our
center was seen in a male from a heterogeneous FIPA
family (34).
† Familial somatotropinomas account for 30% of
tumors seen in FIPA. A further 7% of tumors could
be classified as somatolactotropes, although their
characteristics are not different from somatotropi-
nomas in the FIPA cohort. Somatotropinomas are
equally divided between homogeneous FIPA (essen-
tially IFS) and heterogeneous tumor families.
Notably, patients with IFS are diagnosed about 10
years before those with somatotropinomas in
heterogeneous FIPA kindreds or in sporadic cases, a
finding that echoes previous results on IFS from
other groups. Those with IFS within the FIPA cohort
are also significantly more likely to exhibit extra- or
suprasellar extension of their tumors, with a trend
toward more frequent invasion of surrounding
structures.
† In FIPA, NS adenomas generally occur in hetero-
geneous kindreds (O85%), are diagnosed signi-
ficantly earlier (w8 years), and are more
frequently invasive than their sporadic counterparts.
† Gonadotropinomas, Cushing’s disease, and TSH-
secreting adenomas are all relatively infrequent in
the setting of FIPA (each is !5% of the total
population). They occur in association with other
tumor types in heterogeneous kindreds, although
two homogeneous Cushing’s disease families and
one family with homogeneous gonadotropinoma
phenotype were described in the FIPA cohort.
Pituitary tumors in FIPA differ from those seen in
the setting of MEN1. FIPA patients with homo-
geneous acromegaly (i.e. IFS) or Cushing’s disease
are younger at diagnosis than those with MEN1 (7).
Prolactinomas are the most frequent tumors seen in
FIPA and MEN1 (as they are in the sporadic setting);
however, in MEN1, they account for a much greater
proportion of the total (63%) when compared with
FIPA (40%). In FIPA, somatotropinomas are about
four times more frequent (34.1%) when compared
with MEN1 (8.8%).Genealogical information
Among the full FIPA genealogies studied (mean family
size 15.4 individuals), pituitary tumors occur inw14%of family members. The familiality (degree of relatedness
among affected individuals) of FIPA is high at 0.62,
suggesting that genetic inheritance is at least partly
dominant in character. Maternal transmission is more
common among homogeneous than heterogeneous
FIPA, potentially due to a high number of mother–
daughter homogeneous prolactinoma kindreds (Fig. 2).
A paternal transmission pattern is seen predominantly
in patients with heterogeneous somatotropinomas,
whereas homogeneous somatotropinomas (IFS) was
characterized mainly (65%) by presentation in siblings.The genetics of FIPA
By definition, patients with FIPA have mutations in
neither the MEN1 nor the PRKAR1A gene. In the
clinical studies outlined above, screening for MEN1
mutations was performed in at least one affected
member of each kindred, while PRKAR1A screening
was performed in relevant kindreds with acromegaly.
In IFS kindreds, a series of genetic studies have been
undertaken to out-rule the involvement of mutations in
candidate genes, some in the region of chromosome
11q13. No mutations in gsp, the GH releasing hormone
(GHRH)-receptor gene, or the requiem gene were seen
in IFS kindreds (35–37).
In an important advance, a study by Vierimaa et al. in
May 2006 described a detailed genome-wide screening
and DNA mapping study for genes involved in the
pathogenesis of pituitary tumors that occurred in a
familial setting (21). In these families, combinations of
somatotropinomas, mixed GH–prolactin-secreting
tumors and prolactinomas were seen. In affected
members, the group discovered inactivating mutations
in the gene that encodes AIP on chromosome 11q13.3.
Analysis of tumor samples from affected individuals
noted loss of heterozygosity at the AIP locus, suggesting
that tumors were null for AIP. Two mutations were
found among a Finnish cohort, Q14X in familial and
sporadic pituitary adenoma cases and an IVS3-1GOA
mutation in splice acceptor site of exon 4 in one patient
with a sporadic pituitary adenoma. In addition, an
R304X mutation was described in an Italian sibling pair
with acromegaly, while familial pituitary tumor kin-
dreds in Turkey and Germany demonstrated no AIP
mutations. Given the phenotypic similarities between
families within the FIPA cohort and those reported by
Vierimaa et al. (21), a study was performed to assess
whether AIP mutations contributed significantly to the
pathogenesis of tumors in the setting of FIPA.
In an international cohort from nine countries, 156
patients comprising 73 FIPA families were included
and were classified according to the disease definitions
used in earlier studies of the clinical characteristics of
FIPA (18, 25). A total of 11 out of 73 (15.1%) FIPA
families harbored ten different germline AIP mutations,
one FIPA family from Italy (unrelated to that reported
by Vierimaa et al.) had an R304X mutation, and thewww.eje-online.org
Figure 2 Distribution of first-degree-related
affected members from isolated pituitary
adenoma families. Affected members are
shown by (a) type of relation; (b) potential
parental lineage; (c) potential parental line-
age in families with homogeneous tumor
phenotype expression; and (d) potential
parental lineage in families with hetero-
geneous tumor phenotype expression.
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families with homogeneous acromegaly/IFS demon-
strated AIP mutations. Indeed, the lack of AIP
mutations in FIPA kindreds with apparently strongwww.eje-online.orgfamiliality for pituitary tumors (multiple three-member
kindreds and a four-member family) indicates that
additional causes are involved in the genetic patho-
physiology of FIPA.
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families are outlined in Table 2. The range of patient and
tumor characteristics seen in AIP mutation-positive
FIPA kindreds is quite variable. FIPA patients with AIP
mutations are significantly younger at diagnosis than
those without AIP mutations (w12 years), while their
maximum tumor diameter is significantly larger in the
group with AIP mutations than those without. The
majority of FIPA families with AIP mutations have
somatotropinomas or mixed GH–prolactin-secreting
tumors, but in one FIPA family, a patient with a NS
tumor (negative GH and prolactin immunohisto-
chemistry) occurred in association with a prolactinoma
in the other affected family member. When immuno-
histochemical and hormonal secretion patterns in FIPA
patients with AIP mutations are considered, a further
degree of complexity is added. For instance, patients
classified as having ‘somatotropinomas’ are in fact not a
uniform group, with 62% having elevations in GH and
IGF-I alone, while 38% also had elevated prolactin.
In terms of immunohistochemistry, ‘somatotropinoma’
patients with AIP mutations can demonstrate staining
for GH alone (59%), GH and prolactin (33%), or GH and
FSH (8%). Indeed, the same AIP mutation can lead to
various clinical phenotypes in different familial kin-
dreds, with a somatotropinoma and a prolactinoma
occurring in one family with an R271W mutation, and
only acromegaly occurring in another unrelated family
with the same mutation. The Q14X mutation seen
relatively frequently among familial and sporadic
pituitary tumor patients from Finland was not identified
within FIPA families. The fact that this mutation was
also not identified among larger sporadic and familial
pituitary tumor populations in Europe, Japan, and the
U.S. suggests that it is due to a founder mutation and is
particularly characteristic of pituitary disease in
Northern Finland (38–41).
Many AIP mutations have now been demonstrated in
the setting of isolated pituitary adenomas, both familialTable 2 Characteristics of patients and asymptomatic carriers with A
AIP mutation Relation between members Disease ph
R16H Two first cousins Acromegaly
G47_R54del Two siblings Acromegaly




E174fs Two siblings and a maternal aunt Acromegaly
prolactino
Q217X Two siblings Acromegaly
Q239X Parent and one offspring Acromegaly
K241E Two siblings Prolactinom
adenoma
R271W Parent and one offspring Acromegaly
R271W Parent and one offspring Acromegaly
Q285fs Two siblings Acromegaly
R304X Two siblings and one nephew Acromegalyand more rarely sporadic (Fig. 3). The functional
implications of these mutations in AIP remain to be
determined as relevant studies of protein expression and
ligand–receptor interactions relating to these reported
AIP mutations are wholly lacking. Experimental data on
aspects of the structure of AIP do, however, provide
some useful indicators. AIP, a member of the immuno-
philin family of proteins, is 330 amino acids in length
and contains a number of conserved regions. Among
these are three tetratricopeptide repeat (TPR) domains
and a FK506 binding protein-type peptidyl-prolyl cis–
trans isomerase (FKBP-PPI) domain; the latter is
characteristic of immunophilin proteins. Most infor-
mation available on the structure–function relation-
ships of AIP relate to the third TPR domain and the
carboxy-terminal amino acids (42). The third TPR
domain is required for the interaction of AIP with a
dimer of heat shock protein 90 (hsp90) and with the
aryl hydrocarbon receptor (AhR) (43). Mutations of the
AIP third TPR domain in the mouse prevent or decrease
interactions with hsp90, AhR, or both (44, 45), while
removal of the final carboxy-terminal amino acids
prevents binding to AhR (46).
Many AIP mutations leading to protein truncations
would either prevent AIP being encoded entirely or
would remove the vital third TPR domain and the
carboxy-terminal. Relatively little is known regarding
the function of the amino terminus of AIP; however, its
amino acid sequence is highly conserved across species.
This suggests that amino acid substitutions, such as
R16H for instance, could be expected to have functional
significance. Indeed, since we reported germline R16H
changes in a FIPA family, others have noted similar
mutations in four sporadic pituitary adenoma patients
and also in the germline and tumors of two patients with
colorectal carcinoma (and family histories of colorectal,
carcinoid, and other tumors) (47, 48). A full appreci-
ation of the effect of R16H on AIP expression and/or





2 (mother and sister of affected subjects);






7 (grandparent, parent, and siblings of
affected subjects)
1 (nephew of affected subjects)
/gigantism 3 (grandparent, uncle, and sibling of affected
offspring)




/gigantism 4 (siblings of affected subjects)
www.eje-online.org
Figure 3 The AIP protein with functional domains highlighted and reported genetic mutations noted. FKBP-PPI, FK506 binding protein-type
peptidyl prolyl cis-trans isomerase; TPR, tetratricopeptide repeat domain; hsp90, heat-shock protein 90, AhR, aryl hydrocarbon receptor.
Adapted with permission from Daly AF et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary
adenomas: analysis in 73 families. Journal of Clinical Endocrinology and Metabolism May 2007 92(5) 1891–1896. Copyright 2007, The
Endocrine Society. Reference (25).
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involving conserved residues (R271W and K241E) have
been identified in FIPA families; the former concerns a
highly conserved arginine that forms part of the third
TPR domain. Mutation studies of amino acids in this
region of AIP in the mouse prevent hsp90/AhR binding.
Similarly, K241E is a conserved amino acid, although its
functional role is indeterminate at this time.
To date, most studies related to AIP have focused
primarily on the modulation of dioxin-related cellular
responses via the interaction of AIP with its receptor
AhR and an hsp90 dimer. This is clearly an important
function, with depletion and augmentation of intra-
cellular AIP concentrations leading to enhanced and
decreased ubiquitin-mediated degradation of AhR (49).
However, AhR has been shown to have a wide range of
effects on cellular signaling cascades, not only those
limited to dioxin-mediated responses, e.g. induction of
hepatic cytochrome P450 subtype 1A1 expression.
AhR shares affinity with hypoxia inducible factor-1a
(HIF-1a) for the aryl hydrocarbon nuclear translocatorwww.eje-online.org(ARNT), through which multiple cellular cascades can
be modulated; newer evidence suggests that AhR, HIF-
1a, and ARNT are involved in a complex crosstalk at a
transcriptional level involving multiple response
elements and DNA motifs (50). Crosstalk between
AhR and other transcription factors has been shown
to include nuclear factor-kB, retinoblastoma protein,
and estrogen receptor-a (51). Interestingly, it has been
suggested that AhR–ARNT can modulate estrogen
receptor signaling, potentially explaining the role of
dioxin-related toxins as environmental ‘endocrine
disruptors’ (52). Furthermore, AIP appears to play a
separate role in the selective modulation of the cAMP-
specific phosphodiesterase PDE4A5, with AIP reversibly
inhibiting PDE4A5, and can reduce the ability of protein
kinase to phosphorylate PDE4A5 (53). Interestingly, a
mutation at the arginine at position 271 (a mutation
site in two FIPA families) reduced the interaction of AIP
with PDE4A5. While the effects of AIP modulation of
PDE4A5 on cell proliferation remain to be determined, a
mutation-sensitive effect of AIP on cAMP levels would
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determining the role of AIP mutations in pituitary
tumorigenesis. Recently, a specific interaction of
phosphodiesterase PDE2A with AIP has been reported
that serves to inhibit dioxin- and cAMP-related AhR
nuclear translocation and gene transcription (54).
Given the important role of AIP in modulating AhR
levels, inactivating mutations of AIP appear likely to
interfere with multiple physiological signaling cascades
and xenobiotic responses.Perspectives
The occurrence of tumors in a familial setting
represents a useful starting point for the investigation
of their genetic and molecular tumorigenesis, as
evidenced by the study of MEN1 and CNC. Familial
pituitary adenomas are a typical feature of these and
other newer hereditary neuroendocrine tumor syn-
dromes related to mutations in CDKN1B and AIP.
However, despite molecular genetic advances, the
clinical recognition and practical management remain
the initial step and final goal in dealing with novel
familial endocrine syndromes.
As described above, FIPA encompasses a wider
phenotypic definition of familial pituitary tumors than
permitted by the established condition of IFS, and
virtually all combinations of pituitary tumors can occur
in homogeneous and heterogeneous patterns within
families. Thus, families exhibiting isolated somatotropi-
nomas and prolactinomas can be readily described
using the term FIPA. Furthermore, FIPA can be used to
describe such kindreds in the presence or absence of AIP
mutations, whereas the alternate description of pitu-
itary adenoma predisposition is limited to the minority
of families with a confirmed AIP mutation.
Some years ago, we chose the term FIPA for the
description of our cohort for a number of reasons. First,
it is broad yet clinically descriptive, as befits a label for
an investigative condition of often uncertain molecular
etiology. With the advent of AIP mutations as a
causative agent for familial pituitary adenomas, we
believe that FIPA remains valid as a terminology
particularly given that only 15% of FIPA cases are
linked to AIP mutations. Furthermore, as AIP is thought
to be a culprit in only 50% of IFS cases, IFS also remains
a disease classification with clear clinical utility.
Secondly, FIPA readily follows a naming format similar
to that used in other forms of hereditary hormone
excess and endocrine cancers occurring in single
organs, such as familial isolated hyperparathyroidism
(FIHP) or familial isolated medullary thyroid carcinoma
(FMTC) (55). Both of these conditions, like FIPA, are
described in terms of their clinical and familial nature
(56), but can be caused by various identified genetic
mutations (e.g. MEN1 and HRPT2 for FIHP (57–60),
while linkage to other genes and chromosomal regionshas been suggested in cases without a defined genetic
pathophysiology (61, 62). Similarly, FIPA permits the
accurate clinical description of isolated pituitary tumors
occurring in families while allowing for multiple genetic
causes, such as AIP, and others yet to be described.
Currently, the FIPA cohort, including those with AIP
mutations, remains free of other discrete endocrine and
non-endocrine conditions that would suggest a charac-
teristic clinical syndrome. However, it cannot be
discounted that germline AIP mutations could be
associated with a predisposition to tumors other than
pituitary adenomas particularly as missense AIP
mutations have been noted in the setting of colonic
adenoma tissue. While other highly prevalent tumors,
such as thyroid adenomas, are present in certain FIPA
patients, demonstration of LOH for AIP or abnormal AIP
protein expression would be required before expanding
the clinical phenotype beyond pituitary adenomas.
These questions will be answered in part by the clinical
phenotype exhibited by aip knockout mouse models now
at an advanced stage of development. However, there is
an important caveat in extrapolating murine data on
AIP function to humans because the interactions of AIP
with AhR in the mouse differ from that in the human in
terms of AIP-cytoplasmic localization and AIP-induced
shuttling to the nucleus (63, 64). It may be that this
inter-species divergent AIP/AhR function may lead to
different disease risks and tumor expression in humans
when compared with mice.
With the identification of AIP mutations as being
involved in the etiology of familial pituitary tumors, the
issue of screening has been raised (47). In particular, it has
been suggested that immunohistochemistry for AIP in
pituitary tumor tissue be used to screen operated patients
for mutations. While it is indeed feasible to undertake AIP
immunohistochemistry, further information will be
required on a number of fronts. Initially, the presence or
absence of AIP in pituitary tumor samples requires
information regarding the patterns of expression of AIP
in the nucleus and cytoplasm of normal pituitary cells.
Also, it remains to be determined as to whether various
normal pituitary cells (somatotropes, lactotropes, or
corticotropes) themselves have distinctive levels of AIP
expression. Pituitary adenomas associated with AIP
mutations in FIPA and the sporadic setting are hetero-
geneous in terms of hormonal immunohistochemistry
and clinical phenotype and include all types except for
thyrotropinomas. Again, the range of AIP expression
patterns in these adenomatous cells when compared with
normal tissue remains to be determined before immuno-
histochemical screening can permit identification of AIP-
mutated specimens. The effects of common first-line and
adjunctive treatments (somatostatin analogs, dopamine
agonists, and radiotherapy) on AIP expression patterns in
somatotropinomas, prolactinomas, and NS tumors have
not been studied to date and could theoretically alter
immunohistochemical results. AIP immunohisto-
chemistry has, to date, focused on samples derived fromwww.eje-online.org
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Finnish founder mutation, Q14X). Such mutations would
be expected to lead to an absence of AIP protein and a
negative immunostain. Mutations that lead to the
disruption of crucial amino acids in the third TPR
(R271W) or the carboxy-terminal amino acids (R304X)
may abrogate or decrease biological AIP function without
decreasing protein expression; this could lead to tumor
samples containing mutated AIP protein appearing
normal on immunohistochemistry. Finally, AIP immuno-
histochemistry has been based on murine polyclonal
antibodies that have unknown cross-reactivity patterns
with human immunophilins. For fundamental immuno-
histochemistry studies on AIP expression in normal and
adenomatous pituitary tissues, it would be preferable that
monoclonal antibodies directed against known epitopes
on the human AIP protein should be used.
Widespread genetic screening for AIP mutations in
patients with sporadic pituitary adenomas and in relatives
of those bearing AIP mutations requires careful consider-
ation. First, there is considerable divergence in the
reported penetrance of pituitary adenomas among
kindreds with AIP mutations. In the original report
regarding AIP mutations in familial pituitary adenomas, it
was suggested that this was a low penetrance disease (21).
However, that study was based on a relatively small
number of families (three families with two distinct AIP
mutations) and limited clinical screening of the kindred.
In contrast, we suggest that the penetrance of pituitary
disease in AIP mutation-bearing FIPA kindreds is high.
Our preliminary data would suggest that well in excess of
50% of individuals from families withAIPmutations have
pituitary adenomas, data that are supported by other
groups (65) and are in keeping with the strong reported
familiality of FIPA (18). Before widespread genetic
screening for AIP mutations among pituitary adenoma
patients can be contemplated, the issue of true penetrance
will need to be addressed in order to provide informative
counseling to patients and to address the vital ethical
issues relevant to the study of familial neuroendocrine
tumor syndromes (for review see Sukarai et al. (66)). We
agree with Melmed that the widespread use of genetic and
radiological screening in unselected patients with spora-
dic pituitary adenomas is not warranted at this time (67).
However, given the characteristics of patients with AIP
mutations (young age at diagnosis, large tumor size),
screening of young patients with aggressive pituitary
tumors for AIP mutations should be considered. In the
case of relatives of patients with AIP mutation-related
pituitary adenomas, AIP screening is recommended.
Patients with pituitary tumors and AIP mutations may
have a poorer response to therapy, like many young
patients with larger pituitary tumors (68), although this
issue has not been studied per se. From a clinical
perspective, it may be practical to bear in mind the main
characteristics of patients from FIPA kindreds: (1)
pituitary adenomas of all types can occur in a familial
setting; (2) pituitary tumors in FIPA are larger andwww.eje-online.orgdiagnosed earlier than sporadic adenomas; (3) 15% of
FIPA and 50% of IFS families are linked to mutations in
AIP; and (4) in the absence of a close family history of
pituitary adenomas, AIP mutations are rare. Whatever
the genetic pathophysiology is, good endocrine practice
involving a detailed family history, standard comprehen-
sive testing of pituitary axes, and pituitary MRI should be
applied to all patients with pituitary adenomas. In the case
of young patients with aggressive tumors, germline AIP
genetic study may be useful (69) and is warranted in the
presence of a family history of pituitary tumors without an
identified genetic pathophysiology.Acknowledgements
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